Cure My Disease

Don't miss your cure!

 Log in / Sign up

The hidden handshake that decides whether an embryo implants

NCT ID NCT07825649

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal Creteil Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers want to understand why most IVF embryo transfers fail to implant and what goes wrong in pregnancies complicated by preeclampsia. They will collect small tissue samples from the womb lining of up to 500 women aged 18 to 50 who are already scheduled for a diagnostic hysteroscopy. In the lab, the team will study how those cells interact with early placental cells, looking at gene activity and how deeply placental cells can invade. The goal is to map the molecular steps of early implantation and placentation, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
diagnostic hysteroscopy with endometrial biopsy
What this could lead to
If researchers map how the womb lining and early embryo communicate, this could point toward ways to improve IVF success rates and understand what triggers preeclampsia.
What could go wrong
This is a laboratory study of tissue samples, not a treatment trial, so any clinical benefit is years away. The findings may not translate into new therapies, and the biopsy carries small risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medical indication for a diagnostic hysteroscopy between the ages of 18 and 50 * Comprehensive information provided prior to the hysteroscopy * Informed consent signed by the patient Exclusion Criteria: * Current pregnancy * Age \< 18 or \> 50 * Patient refusal * Woman under court-ordered protection * Not enrolled in the general social security system * Patient who is HIV- or HCV-positive, regardless of viral load * Patient whose medical history requires medication that may interfere with trophoblast biology (immunomodulators in cases of autoimmune diseases, anti-rejection drugs in transplant patients) * Known genetic disorder in the patient * Unable to understand and sign the consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eclampsia preeclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eclampsia preeclampsia Infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chi Creteil

    Créteil, 94000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.